8-K: Tango Therapeutics Reports Strong Phase 1/2 Data for Cancer Combo

Tango Therapeutics announced highly encouraging initial safety and efficacy data from its Phase 1/2 combination trial of vopimetostat with RAS(ON) inhibitors in pancreatic cancer patients.

Summary

• Tango Therapeutics presented initial data from a Phase 1/2 trial evaluating vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors (daraxonrasib or zoldonrasib) in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC).
• In the vopimetostat plus daraxonrasib arm for PDAC patients (n=12), an objective response rate (ORR) of 92% was observed, with 90% achieving a six-month progression-free survival (PFS) rate and a 100% disease control rate (DCR).
• For NSCLC patients (n=3) in the same arm, the ORR was 100%.
• The vopimetostat plus zoldonrasib arm in PDAC patients (n=27) showed an ORR of 52%, a 74% six-month PFS rate, and a 96% DCR.
• Both combinations were generally well-tolerated, with most adverse events being Grade 1 or 2, and no related Grade 4 or 5 adverse events or discontinuations due to adverse events were reported.
• Based on these results, Tango plans to advance the vopimetostat plus daraxonrasib combination into Phase 3 development for first-line MTAP-deleted pancreatic cancer.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive development, with exceptionally strong efficacy data and a favorable safety profile, paving the way for Phase 3 trials and potential regulatory approval.

Positives

• Objective response rate (ORR) of 92% in PDAC patients treated with vopimetostat plus daraxonrasib.
• 90% six-month progression-free survival (PFS) rate in PDAC patients treated with vopimetostat plus daraxonrasib.
• 100% disease control rate (DCR) in PDAC patients treated with vopimetostat plus daraxonrasib.
• 100% ORR in NSCLC patients treated with vopimetostat plus daraxonrasib.
• 52% ORR in PDAC patients treated with vopimetostat plus zoldonrasib.
• Generally well-tolerated safety profile for both combinations with no Grade 4 or 5 adverse events.
• No discontinuations due to adverse events reported for either combination.
• Plans to advance the vopimetostat plus daraxonrasib combination into Phase 3 development for first-line pancreatic cancer.

Negatives

• Three dose-limiting toxicities (DLTs) were reported in two patients at the higher dose level (vopimetostat 250mg/daraxonrasib 100 mg) in the daraxonrasib arm, including Grade 3 rash and Grade 3 stomatitis/fatigue.
• The vopimetostat plus zoldonrasib combination showed a lower ORR of 52% compared to the daraxonrasib combination.

Risks

• The benefits of product candidates seen in preclinical tests and analyses may not be evident when tested in later preclinical studies or in clinical trials or when used in broader patient populations.
• Future clinical trial data releases may differ materially from initial or interim data.
• Regulatory developments in the United States and foreign countries could impact development.
• The company's ability to fund operations is a risk.
• The company has limited experience conducting clinical trials and may not be able to commence or progress trials as expected.
• Pipeline products may not be safe and/or effective in humans.
• The company will need to raise capital in the future, and failure to do so could force delays or discontinuation of development programs.
• Product candidates may cause adverse or other undesirable side effects that could delay or prevent regulatory approval.

Future Outlook

Tango Therapeutics intends to advance the vopimetostat plus daraxonrasib combination into Phase 3 development for first-line MTAP-deleted pancreatic cancer, subject to regulatory feedback. The company also plans to initiate a Phase 3 randomized-controlled trial in front-line pancreatic cancer and evaluate opportunities for the second-line combination towards registration. Additional data readouts for vopimetostat monotherapy in lung cancer and TNG456 in GBM are expected in the second half of 2026, along with the initiation of a Phase 1/2 vopimetostat + ERAS-0015 combination study.

Management Comments

• "In the first reported data from the clinical combinations of our PRMT5 inhibitor vopimetostat and RAS(ON) inhibitors, we saw extremely encouraging early results, with 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response, supporting the preclinical data showing synergistic activity of PRMT5 + RAS inhibition."
• "Equally important, we are seeing encouraging signals of durability, with 90% of PDAC patients still progression free at 6 months of follow up. In addition, both combinations were generally well tolerated."
• "Our primary focus is now to bring forward the PRMT5 plus RAS inhibitor combination approach in pancreatic cancer, while also looking toward important upcoming data readouts for vopimetostat single agent in lung cancer and TNG456 in GBM which we believe represents significant long-term opportunity for our company."
• "These compelling results reinforce our belief that a vopimetostat-based combination with RAS inhibitors may be a path to a chemotherapy-free option for patients with MTAP-deleted pancreatic cancer. Given these data, we intend to prioritize advancement of the vopimetostat plus daraxonrasib combination into Phase 3 development in first-line, MTAP- deleted pancreatic cancer."

Industry Context

StockSavvy.ai notes that these results position Tango Therapeutics at the forefront of a potential shift in pancreatic cancer treatment, moving towards precision-guided, chemotherapy-free options for patients with specific genetic mutations (MTAP-deleted and RAS-mutant). The high ORR and PFS rates observed in heavily pre-treated patients are particularly significant in a disease with limited effective therapies.

Comparison to Industry Standards

• The observed 92% ORR in the vopimetostat + daraxonrasib arm for second/third-line PDAC patients significantly surpasses historical ORRs for standard chemotherapy regimens in similar patient populations, which typically range from 15-30%.
• The 90% six-month PFS rate in this arm also appears to be a notable improvement over historical benchmarks for second/third-line PDAC treatment.
• While direct comparisons are challenging due to differing trial designs and patient populations, the efficacy signals from this Phase 1/2 trial suggest a potentially transformative impact compared to current standards of care for MTAP-deleted, RAS-mutant pancreatic cancer.

Stakeholder Impact

• Shareholders: Positive impact expected due to strong clinical data potentially leading to future drug approval and revenue generation.
• Patients: Significant potential benefit from a new, highly effective, and potentially chemotherapy-free treatment option for pancreatic cancer.
• Healthcare Providers: Opportunity to offer a novel therapeutic approach for a difficult-to-treat cancer.
• Regulators: Data will be reviewed for potential advancement to Phase 3 and eventual approval.

Next Steps

• Finalize design of Phase 3 randomized-controlled trial of the vopimetostat + daraxonrasib combination in front-line pancreatic cancer in 2H 2026.
• Disclose vopimetostat lung cancer monotherapy data in 2H 2026.
• Release initial TNG456 glioblastoma data in 2H 2026.
• Present 2/3L PDAC vopimetostat + RAS(ON) inhibitors combination data at a scientific conference in 2H 2026.
• Initiate Phase 1/2 vopimetostat + ERAS-0015 combination study in 2H 2026.

Key Dates

Recommendation

The presented data show exceptionally high response rates and good tolerability in a difficult-to-treat cancer indication, significantly de-risking the asset and providing a clear path to Phase 3 development. This represents a substantial positive catalyst for Tango Therapeutics.

Keywords

Tango Therapeutics, vopimetostat, daraxonrasib, zoldonrasib, pancreatic cancer, PRMT5 inhibitor, RAS(ON) inhibitor, oncology